MUMBAI, India, Feb. 27 -- Intellectual Property India has published a patent application (202641017972 A) filed by M. Harini, Namakkal, Tamil Nadu, on Feb. 18, for 'development of novel sustained release formulations forenhanced bioavailability of anti-diabetic drugs.'
Inventor(s) include M. Harini; Preetha V; M. Madhumitha; and Pradeep Kumar. M.
The application for the patent was published on Feb. 27, under issue no. 09/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to novel sustained release formulations of anti-diabetic drugs designed to enhance bioavailability and therapeutic efficacy. The formulations comprise active pharmaceutical ingredients including metformin, sulfonylureas, or newer agents encapsulated within advanced polymer matrices or lipid-based delivery systems. These systems are engineered to achieve prolonged drug release over 12-24 hours, reducing dosing frequency from multiple times daily to once or twice daily administration. The invention encompasses formulation compositions, manufacturing methods, pharmaceutical and dosage forms, and their therapeutic applications in managing Type 2 diabetes mellitus with improved patient compliance and reduced gastrointestinal side effects. The sustained release technology enables constant plasma concentration levels, minimizing hyperglycemic episodes and reducing the risk of drug-induced hypoglycemia. Comparative in vivo and in vitro studies demonstrate superior bioavailability profiles compared to conventional immediate release formulations, with area under curve improvements ranging from 25-40%. The patent scope includes individual drug formulations, combination therapies, manufacturing processes utilizing polymer blending, microencapsulation, and matrix formation techniques with pharmaceutical excipients. Clinical data supports enhanced glycemic control and improved patient quality of life metrics in diabetic populations."
Disclaimer: Curated by HT Syndication.
